Furthermore, early phase clinical trials found that anti-CD22 chimeric receptor T cells exhibited similar antitumor effects as CD19-targeted therapies and had the potential to be an alternative treatment for relapsed or refractory pre-B-ALL (5). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.